Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Chronic gastritis; Peptic ulcer 1 g 4 times/day for 4-8 wk, up to 12 wk if needed. Maintenance: 1 g bid to prevent the recurrence of duodenal ulcers. Max: 8 g/day. Prophylaxis of GI haemorrhage from stress ulceration 1 g 6 times/day. Up to 8 g/day.
Dosage Details
Peptic ulcer
Adult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Maintenance dose to prevent the recurrence of duodenal ulcers: 1 g bid. Max: 8 g daily.

Chronic gastritis
Adult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Max: 8 g daily.

Prophylaxis of gastrointestinal haemorrhage from stress ulceration
Adult: 1 g 6 times daily. Max: 8 g daily.
Should be taken on an empty stomach. Take 1 hr before or 2 hr after meals.
Special Precautions
Patient w/ known conditions that may impair swallowing (e.g. recent or prolonged intubation, tracheostomy, dysphagia). Renal impairment. Pregnancy and lactation.
Adverse Reactions
Nervous: Headache, dizziness, drowsiness, insomnia, vertigo.
GI: Constipation, diarrhoea, nausea, vomiting, flatulence, indigestion, gastric discomfort, dry mouth.
Musculoskeletal: Back pain.
Dermatologic: Pruritus, skin rash.
Drug Interactions
May increase total body burden of Al w/ drugs that contain Al (e.g. Al-containing antacids). May reduce absorption of tetracyclines, ranitidine, ketoconazole, theophylline, phenytoin, cimetidine, ciprofloxacin, norfloxacin and digoxin.
Description: Sucralfate protects GI lining against peptic acid, pepsin and bile salts by binding w/ positively-charged proteins in exudates forming a viscous paste-like adhesive substance thus forming a protective coating.
Onset: 1-2 hr.
Duration: 6 hr.
Absorption: Minimally absorbed from the GI tract.
Distribution: Acts locally at ulcer sites; unbound in GI tract to aluminum and sucrose octasulfate.
Excretion: Mainly via urine.
Chemical Structure

Click on icon to see table/diagram/image
Store between 20-25°C.
ATC Classification
A02BX02 - sucralfate ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Disclaimer: This information is independently developed by MIMS based on Sucralfate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
  • Apo-Sucralfate
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in